New drug AZD9592 enters first human trials for tough cancers

NCT ID NCT05647122

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Because it is a first-in-human study, the results will help decide if larger trials should move forward.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD9592 (an experimental drug given intravenously)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early (Phase 1) trial with only 167 participants, so the drug may not be effective or could cause unexpected side effects. It is not yet known if AZD9592 will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm head and neck neoplasm Head and Neck Neoplasms head and neck squamous cell carcinoma neoplasm non-small cell lung carcinoma oral cavity squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOURS CARCINOMA, NON-SMALL-CELL LUNG COLORECTAL NEOPLASMS HEAD AND NECK NEOPLASMS

Contacts and locations

Locations

Research Site

Duarte, California, 91010, United States
Research Site

North Haven, Connecticut, 06473, United States
Research Site

Washington D.C., District of Columbia, 20016, United States
Research Site

Chicago, Illinois, 60637, United States
Research Site

Baltimore, Maryland, 21224, United States
Research Site

Baltimore, Maryland, 21231, United States
Research Site

Milford, Massachusetts, 01757, United States
Research Site

Mineola, New York, 11501, United States
Research Site

New York, New York, 10016, United States
Research Site

New York, New York, 10021, United States
Research Site

New York, New York, 10029, United States
Research Site

Philadelphia, Pennsylvania, 19104, United States
Research Site

Providence, Rhode Island, 02903, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Fairfax, Virginia, 22031, United States
Research Site

Kogarah, 2217, Australia
Research Site

Melbourne, 3000, Australia
Research Site

Edmonton, Alberta, T6G 1Z2, Canada
Research Site

Toronto, Ontario, M5G 1X6, Canada
Research Site

Beijing, 100142, China
Research Site

Chongqing, 400030, China
Research Site

Guangzhou, 510100, China
Research Site

Wuhan, 430022, China
Research Site

Marseille, 13385, France
Research Site

Rennes, 35000, France
Research Site

Villejuif, 94805, France
Research Site

Milan, 20162, Italy
Research Site

Orbassano, 10043, Italy
Research Site

Rozzano, 20089, Italy
Research Site

Verona, 37134, Italy
Research Site

Chūōku, 104-0045, Japan
Research Site

Kashiwa, 277-8577, Japan
Research Site

Kōtoku, 135-8550, Japan
Research Site

Kuala Lumpur, 59100, Malaysia
Research Site

Kuching, 93586, Malaysia
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Barcelona, 8035, Spain
Research Site

Madrid, 28040, Spain
Research Site

Seville, 41013, Spain
Research Site

Taichung, 40705, Taiwan
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 11217, Taiwan
Research Site

Taoyuan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.